Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
Background The high postoperative recurrence rate of hepatocellular carcinoma (HCC) is a significant challenge. Patient metabolic factors are potential disease modifiers and should be examined as risk factors for postoperative prognosis. Here, we assessed the association between long‐term statin use...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical investigation 2023-04, Vol.53 (4), p.e13936-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 4 |
| container_start_page | e13936 |
| container_title | European journal of clinical investigation |
| container_volume | 53 |
| creator | Yun, Byungyoon Ahn, Sang Hoon Oh, Juyeon Yoon, Jin‐Ha Kim, Beom Kyung |
| description | Background
The high postoperative recurrence rate of hepatocellular carcinoma (HCC) is a significant challenge. Patient metabolic factors are potential disease modifiers and should be examined as risk factors for postoperative prognosis. Here, we assessed the association between long‐term statin use and HCC recurrence after surgical resection of hepatitis B virus (HBV)‐related HCC.
Methods
Patients who initially underwent curative resection for HBV‐related HCC between 2005 and 2015 were recruited and followed up until December 2019. Patients were classified into statin user and non‐statin user groups based on whether or not they had been prescribed statins for ≥2 years. The primary outcome was HCC recurrence, and the secondary outcome was liver‐related mortality. The cumulative incidence by statin use was estimated using the Kaplan–Meier method and compared using the log‐rank test. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.
Results
Among 5653 patients with a median 6.1 years of follow‐up, HCC recurrence and liver‐related mortality occurred in 1603 and 316 patients, respectively. The 5‐year cumulative incidence of HCC recurrence in the statin user group (15.9%) was significantly lower than that in the non‐user group (21.3%; p = .019). From multivariable Cox regression analysis, statin use was significantly associated with a reduced risk of HCC recurrence (aHR 0.77, 95% CI: 0.61–0.98; p = .035) and liver‐related mortality (aHR 0.48, 95% CI: 0.25–0.90; p = .023).
Conclusion
Long‐term statin use was significantly associated with reduced risk of HCC recurrence and liver‐related mortality after curative resection of HBV‐related HCC. |
| doi_str_mv | 10.1111/eci.13936 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2753666039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2753666039</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-1428f7493ac6bcc226ced7610afdc3b54aa9528214ae9f0f08a9dbaa95f51f783</originalsourceid><addsrcrecordid>eNp1kT1PxSAUhonR6PXq4B8wJC46VPloaTvqjV-JiYM6N5SeKqYtFajGzdHR3-gvkd6qg4kshHOe9-XAi9AOJYc0rCNQ-pDynIsVNKNcJBHjgq2iGSE0jliesg206dwjISSjnK2jjcCQOCbJDL3feOl1hwcHWDssnTNKSw8VftH-AZfgPVjcG-c_3z5MDzbQz4B7a-4740ZFa7p73IcydN5NqgcYzz50T_CztoMLWgvN0nbZMwqaZmikxUpapTvTyi20VsvGwfb3Pkd3Z6e3i4vo6vr8cnF8FSmecBHRmGV1GudcKlEqxZhQUKWCEllXipdJLGWesIzRWEJek5pkMq_KsVgntE4zPkf7k294wtMAzhetduM4sgMzuIKl4RohSPjOOdr7gz6awXZhukBlSZ7xlKSBOpgoZY1zFuqit7qV9rWgpBjjKUI8xTKewO5-Ow5lC9Uv-ZNHAI4m4EU38Pq_U3G6uJwsvwDpmp5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785983707</pqid></control><display><type>article</type><title>Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yun, Byungyoon ; Ahn, Sang Hoon ; Oh, Juyeon ; Yoon, Jin‐Ha ; Kim, Beom Kyung</creator><creatorcontrib>Yun, Byungyoon ; Ahn, Sang Hoon ; Oh, Juyeon ; Yoon, Jin‐Ha ; Kim, Beom Kyung</creatorcontrib><description>Background
The high postoperative recurrence rate of hepatocellular carcinoma (HCC) is a significant challenge. Patient metabolic factors are potential disease modifiers and should be examined as risk factors for postoperative prognosis. Here, we assessed the association between long‐term statin use and HCC recurrence after surgical resection of hepatitis B virus (HBV)‐related HCC.
Methods
Patients who initially underwent curative resection for HBV‐related HCC between 2005 and 2015 were recruited and followed up until December 2019. Patients were classified into statin user and non‐statin user groups based on whether or not they had been prescribed statins for ≥2 years. The primary outcome was HCC recurrence, and the secondary outcome was liver‐related mortality. The cumulative incidence by statin use was estimated using the Kaplan–Meier method and compared using the log‐rank test. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.
Results
Among 5653 patients with a median 6.1 years of follow‐up, HCC recurrence and liver‐related mortality occurred in 1603 and 316 patients, respectively. The 5‐year cumulative incidence of HCC recurrence in the statin user group (15.9%) was significantly lower than that in the non‐user group (21.3%; p = .019). From multivariable Cox regression analysis, statin use was significantly associated with a reduced risk of HCC recurrence (aHR 0.77, 95% CI: 0.61–0.98; p = .035) and liver‐related mortality (aHR 0.48, 95% CI: 0.25–0.90; p = .023).
Conclusion
Long‐term statin use was significantly associated with reduced risk of HCC recurrence and liver‐related mortality after curative resection of HBV‐related HCC.</description><identifier>ISSN: 0014-2972</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1111/eci.13936</identifier><identifier>PMID: 36504405</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Carcinoma, Hepatocellular - virology ; chronic hepatitis B ; Female ; HCC ; Hepatitis ; Hepatitis B ; Hepatitis B virus ; Hepatocellular carcinoma ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Liver ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Liver Neoplasms - virology ; Male ; Middle Aged ; Mortality ; Neoplasm Recurrence, Local - epidemiology ; Prognosis ; Rank tests ; recurrence ; Regression analysis ; Risk Assessment ; Risk factors ; Risk management ; statin ; Statins ; Statistical analysis ; surgical resection ; User groups ; Viruses</subject><ispartof>European journal of clinical investigation, 2023-04, Vol.53 (4), p.e13936-n/a</ispartof><rights>2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd</rights><rights>2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2023 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-1428f7493ac6bcc226ced7610afdc3b54aa9528214ae9f0f08a9dbaa95f51f783</citedby><cites>FETCH-LOGICAL-c3536-1428f7493ac6bcc226ced7610afdc3b54aa9528214ae9f0f08a9dbaa95f51f783</cites><orcidid>0000-0002-5363-2496</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Feci.13936$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Feci.13936$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36504405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yun, Byungyoon</creatorcontrib><creatorcontrib>Ahn, Sang Hoon</creatorcontrib><creatorcontrib>Oh, Juyeon</creatorcontrib><creatorcontrib>Yoon, Jin‐Ha</creatorcontrib><creatorcontrib>Kim, Beom Kyung</creatorcontrib><title>Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description>Background
The high postoperative recurrence rate of hepatocellular carcinoma (HCC) is a significant challenge. Patient metabolic factors are potential disease modifiers and should be examined as risk factors for postoperative prognosis. Here, we assessed the association between long‐term statin use and HCC recurrence after surgical resection of hepatitis B virus (HBV)‐related HCC.
Methods
Patients who initially underwent curative resection for HBV‐related HCC between 2005 and 2015 were recruited and followed up until December 2019. Patients were classified into statin user and non‐statin user groups based on whether or not they had been prescribed statins for ≥2 years. The primary outcome was HCC recurrence, and the secondary outcome was liver‐related mortality. The cumulative incidence by statin use was estimated using the Kaplan–Meier method and compared using the log‐rank test. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.
Results
Among 5653 patients with a median 6.1 years of follow‐up, HCC recurrence and liver‐related mortality occurred in 1603 and 316 patients, respectively. The 5‐year cumulative incidence of HCC recurrence in the statin user group (15.9%) was significantly lower than that in the non‐user group (21.3%; p = .019). From multivariable Cox regression analysis, statin use was significantly associated with a reduced risk of HCC recurrence (aHR 0.77, 95% CI: 0.61–0.98; p = .035) and liver‐related mortality (aHR 0.48, 95% CI: 0.25–0.90; p = .023).
Conclusion
Long‐term statin use was significantly associated with reduced risk of HCC recurrence and liver‐related mortality after curative resection of HBV‐related HCC.</description><subject>Aged</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>chronic hepatitis B</subject><subject>Female</subject><subject>HCC</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver Neoplasms - virology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Prognosis</subject><subject>Rank tests</subject><subject>recurrence</subject><subject>Regression analysis</subject><subject>Risk Assessment</subject><subject>Risk factors</subject><subject>Risk management</subject><subject>statin</subject><subject>Statins</subject><subject>Statistical analysis</subject><subject>surgical resection</subject><subject>User groups</subject><subject>Viruses</subject><issn>0014-2972</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kT1PxSAUhonR6PXq4B8wJC46VPloaTvqjV-JiYM6N5SeKqYtFajGzdHR3-gvkd6qg4kshHOe9-XAi9AOJYc0rCNQ-pDynIsVNKNcJBHjgq2iGSE0jliesg206dwjISSjnK2jjcCQOCbJDL3feOl1hwcHWDssnTNKSw8VftH-AZfgPVjcG-c_3z5MDzbQz4B7a-4740ZFa7p73IcydN5NqgcYzz50T_CztoMLWgvN0nbZMwqaZmikxUpapTvTyi20VsvGwfb3Pkd3Z6e3i4vo6vr8cnF8FSmecBHRmGV1GudcKlEqxZhQUKWCEllXipdJLGWesIzRWEJek5pkMq_KsVgntE4zPkf7k294wtMAzhetduM4sgMzuIKl4RohSPjOOdr7gz6awXZhukBlSZ7xlKSBOpgoZY1zFuqit7qV9rWgpBjjKUI8xTKewO5-Ow5lC9Uv-ZNHAI4m4EU38Pq_U3G6uJwsvwDpmp5A</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Yun, Byungyoon</creator><creator>Ahn, Sang Hoon</creator><creator>Oh, Juyeon</creator><creator>Yoon, Jin‐Ha</creator><creator>Kim, Beom Kyung</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5363-2496</orcidid></search><sort><creationdate>202304</creationdate><title>Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma</title><author>Yun, Byungyoon ; Ahn, Sang Hoon ; Oh, Juyeon ; Yoon, Jin‐Ha ; Kim, Beom Kyung</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-1428f7493ac6bcc226ced7610afdc3b54aa9528214ae9f0f08a9dbaa95f51f783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>chronic hepatitis B</topic><topic>Female</topic><topic>HCC</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver Neoplasms - virology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Prognosis</topic><topic>Rank tests</topic><topic>recurrence</topic><topic>Regression analysis</topic><topic>Risk Assessment</topic><topic>Risk factors</topic><topic>Risk management</topic><topic>statin</topic><topic>Statins</topic><topic>Statistical analysis</topic><topic>surgical resection</topic><topic>User groups</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yun, Byungyoon</creatorcontrib><creatorcontrib>Ahn, Sang Hoon</creatorcontrib><creatorcontrib>Oh, Juyeon</creatorcontrib><creatorcontrib>Yoon, Jin‐Ha</creatorcontrib><creatorcontrib>Kim, Beom Kyung</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yun, Byungyoon</au><au>Ahn, Sang Hoon</au><au>Oh, Juyeon</au><au>Yoon, Jin‐Ha</au><au>Kim, Beom Kyung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2023-04</date><risdate>2023</risdate><volume>53</volume><issue>4</issue><spage>e13936</spage><epage>n/a</epage><pages>e13936-n/a</pages><issn>0014-2972</issn><eissn>1365-2362</eissn><abstract>Background
The high postoperative recurrence rate of hepatocellular carcinoma (HCC) is a significant challenge. Patient metabolic factors are potential disease modifiers and should be examined as risk factors for postoperative prognosis. Here, we assessed the association between long‐term statin use and HCC recurrence after surgical resection of hepatitis B virus (HBV)‐related HCC.
Methods
Patients who initially underwent curative resection for HBV‐related HCC between 2005 and 2015 were recruited and followed up until December 2019. Patients were classified into statin user and non‐statin user groups based on whether or not they had been prescribed statins for ≥2 years. The primary outcome was HCC recurrence, and the secondary outcome was liver‐related mortality. The cumulative incidence by statin use was estimated using the Kaplan–Meier method and compared using the log‐rank test. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.
Results
Among 5653 patients with a median 6.1 years of follow‐up, HCC recurrence and liver‐related mortality occurred in 1603 and 316 patients, respectively. The 5‐year cumulative incidence of HCC recurrence in the statin user group (15.9%) was significantly lower than that in the non‐user group (21.3%; p = .019). From multivariable Cox regression analysis, statin use was significantly associated with a reduced risk of HCC recurrence (aHR 0.77, 95% CI: 0.61–0.98; p = .035) and liver‐related mortality (aHR 0.48, 95% CI: 0.25–0.90; p = .023).
Conclusion
Long‐term statin use was significantly associated with reduced risk of HCC recurrence and liver‐related mortality after curative resection of HBV‐related HCC.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36504405</pmid><doi>10.1111/eci.13936</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5363-2496</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2972 |
| ispartof | European journal of clinical investigation, 2023-04, Vol.53 (4), p.e13936-n/a |
| issn | 0014-2972 1365-2362 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2753666039 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - virology chronic hepatitis B Female HCC Hepatitis Hepatitis B Hepatitis B virus Hepatocellular carcinoma Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Liver Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Liver Neoplasms - virology Male Middle Aged Mortality Neoplasm Recurrence, Local - epidemiology Prognosis Rank tests recurrence Regression analysis Risk Assessment Risk factors Risk management statin Statins Statistical analysis surgical resection User groups Viruses |
| title | Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T09%3A04%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Statin%20use%20is%20associated%20with%20better%20post%E2%80%90operative%20prognosis%20among%20patients%20with%20hepatitis%20B%20virus%E2%80%90related%20hepatocellular%20carcinoma&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Yun,%20Byungyoon&rft.date=2023-04&rft.volume=53&rft.issue=4&rft.spage=e13936&rft.epage=n/a&rft.pages=e13936-n/a&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1111/eci.13936&rft_dat=%3Cproquest_cross%3E2753666039%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785983707&rft_id=info:pmid/36504405&rfr_iscdi=true |